8 Knots Management LLC Takes Position in DaVita Inc. (NYSE:DVA)

8 Knots Management LLC bought a new stake in shares of DaVita Inc. (NYSE:DVA) during the fourth quarter, HoldingsChannel.com reports. The fund bought 854,372 shares of the company’s stock, valued at approximately $89,504,000. DaVita makes up about 16.8% of 8 Knots Management LLC’s holdings, making the stock its largest holding.

A number of other hedge funds have also recently modified their holdings of the business. Hanseatic Management Services Inc. bought a new position in DaVita in the third quarter worth approximately $36,000. Principal Securities Inc. bought a new position in DaVita in the fourth quarter worth approximately $37,000. GAMMA Investing LLC bought a new position in DaVita in the fourth quarter worth approximately $60,000. Quest Partners LLC bought a new position in DaVita in the fourth quarter worth approximately $74,000. Finally, Tacita Capital Inc bought a new position in DaVita in the third quarter worth approximately $118,000. Institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on DVA. Truist Financial increased their target price on DaVita from $135.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, May 15th. UBS Group increased their target price on DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. StockNews.com cut DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, Barclays increased their target price on DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a research report on Monday, May 6th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $144.67.

DaVita Stock Down 1.2 %

Shares of DVA traded down $1.72 during midday trading on Tuesday, hitting $139.86. 715,644 shares of the company’s stock traded hands, compared to its average volume of 841,693. DaVita Inc. has a 1 year low of $71.51 and a 1 year high of $147.93. The firm’s fifty day moving average is $136.87 and its 200-day moving average is $123.17. The company has a current ratio of 1.43, a quick ratio of 1.37 and a debt-to-equity ratio of 7.95. The stock has a market capitalization of $12.27 billion, a price-to-earnings ratio of 15.89, a price-to-earnings-growth ratio of 1.09 and a beta of 0.96.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, beating the consensus estimate of $1.95 by $0.43. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The firm had revenue of $3.07 billion during the quarter, compared to analyst estimates of $3.03 billion. During the same quarter in the prior year, the business posted $1.58 EPS. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that DaVita Inc. will post 9.62 earnings per share for the current year.

Insider Activity

In related news, Director Barbara J. Desoer sold 5,030 shares of the firm’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $138.81, for a total value of $698,214.30. Following the completion of the transaction, the director now owns 10,954 shares in the company, valued at approximately $1,520,524.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.00% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.